REVIEW OF NICE'S TECHNOLOGY APPRAISAL RECOMMENDATIONS

被引：0
|
作者：
Rinaldi, F. [1 ]
George, E. [1 ]
Longson, C. [1 ]
机构：
[1] Natl Inst Hlth & Clin Excellence, London, England
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.704
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A317 / A318
页数：2
相关论文
共 50 条
  • [21] AN EXAMINATION OF DELAYS DURING NICE TECHNOLOGY APPRAISAL REVIEWS
    Ambrose, S.
    Naci, H.
    Chesters, C.
    Osipenko, L.
    Mossialos, E.
    VALUE IN HEALTH, 2018, 21 : S199 - S199
  • [22] Cladribine tablets and multiple sclerosis: NICE technology appraisal
    Gaber, Tarek
    Shippen, Clare
    PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2018, 22 (01) : 5 - 6
  • [23] The Type and Impact of Evidence Review Group Exploratory Analyses in the NICE Single Technology Appraisal Process
    Carroll, Christopher
    Kaltenthaler, Eva
    Hill-McManus, Daniel
    Scope, Alison
    Holmes, Michael
    Rice, Stephen
    Rose, Micah
    Tappenden, Paul
    Woolacott, Nerys
    VALUE IN HEALTH, 2017, 20 (06) : 785 - 791
  • [24] Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
    Micah Rose
    Jonathan Shepherd
    Petra Harris
    Karen Pickett
    Joanne Lord
    PharmacoEconomics, 2018, 36 : 1299 - 1308
  • [25] Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Ben Wijnen
    Willem Witlox
    Robert Wolff
    Debra Fayter
    Bram Ramaekers
    Thomas Otten
    Steve Ryder
    Pawel Posadzki
    Gill Worthy
    Lisa Stirk
    Nigel Armstrong
    Jos Kleijnen
    Manuela Joore
    PharmacoEconomics, 2023, 41 : 33 - 42
  • [26] Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Wijnen, Ben
    Witlox, Willem
    Wolff, Robert
    Fayter, Debra
    Ramaekers, Bram
    Otten, Thomas
    Ryder, Steve
    Posadzki, Pawel
    Worthy, Gill
    Stirk, Lisa
    Armstrong, Nigel
    Kleijnen, Jos
    Joore, Manuela
    PHARMACOECONOMICS, 2023, 41 (01) : 33 - 42
  • [27] Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Nigel Fleeman
    James Mahon
    Sarah Nevitt
    Rui Duarte
    Angela Boland
    Eleanor Kotas
    Yenal Dundar
    Joanne McEntee
    Sajjad Ahmad
    PharmacoEconomics - Open, 2019, 3 : 453 - 461
  • [28] Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal
    Armoiry, Xavier
    Connock, Martin
    Tsertsvadze, Alexander
    Cummins, Ewen
    Melendez-Torres, G. J.
    Royle, Pam
    Clarke, Aileen
    PHARMACOECONOMICS, 2018, 36 (09) : 1073 - 1081
  • [29] Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal
    Xavier Armoiry
    Martin Connock
    Alexander Tsertsvadze
    Ewen Cummins
    G. J. Melendez-Torres
    Pam Royle
    Aileen Clarke
    PharmacoEconomics, 2018, 36 : 1073 - 1081
  • [30] Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Fleeman, Nigel
    Mahon, James
    Nevitt, Sarah
    Duarte, Rui
    Boland, Angela
    Kotas, Eleanor
    Dundar, Yenal
    McEntee, Joanne
    Ahmad, Sajjad
    PHARMACOECONOMICS-OPEN, 2019, 3 (04) : 453 - 461
12345